A Pipeline Powered by Passion

A Pipeline Powered by Passion

Commercial Medicine & Pipeline

We're advancing muscle-directed potential treatments for diseases characterized by compromised muscle function, muscle weakness, and fatigue.

Therapeutic Area (Clinical Trial)
Research Pre-Clinical Phase 1 Phase 2 Phase 3 Approved &
Commercialized
MYQORZO®*
oHCM
SEQUOIA-HCM

Approved in U.S.
China, & EU**

Aficamten
oHCM (vs. metoprolol)
MAPLE-HCM
Pediatric oHCM
CEDAR-HCM
Phase 2
nHCM
ACACIA-HCM
Phase 3
Ulacamten
HFpEF
AMBER-HFpEF
Phase 2
Omecamtiv Mecarbil
HFrEF
COMET-HF
Phase 3
CK-089
Muscular Dystrophy, Other
Phase 1
Research
Muscular Biology Directed
Research
MYQORZO®*
oHCM
SEQUOIA-HCM
Research
Pre-Clinical
Phase 1
Phase 2
Phase 3
Approved &
Commercialized

Approved in US, China, & EU**

Aficamten
nHCM
ACACIA-HCM
Research
Pre-Clinical
Phase 1
Phase 2
Phase 3
Ulacamten
HFpEF
AMBER-HFpEF
Research
Pre-Clinical
Phase 1
Phase 2
Omecamtiv Mecarbil
HFrEF
COMET-HF
Research
Pre-Clinical
Phase 1
Phase 2
Phase 3
CK-089
Muscular Dystrophy, Other
Research
Pre-Clinical
Phase 1
Research
Muscular Biology Directed
Research

*Please see full Prescribing Information, including Boxed WARNING and Medication Guide

**MYQORZO® is only approved in the U.S., China and the EU for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms.

Ulacamten, omecamtiv mecarbil and CK-089 are investigational agents and have not been approved for use by any regulatory agency. Their safety and efficacy has not been established.

oHCM: obstructive hypertrophic cardiomyopathy; nHCM: non-obstructive hypertrophic cardiomyopathy; HFpEF: heart failure with preserved ejection fraction; HFrEF: heart failure with reduced ejection fraction